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Background: Bosutinib is a recently approved ABL inhibitor. In spite of the well-documented effectiveness of BCR-ABL
inhibitors in treating chronic myeloid leukemia, development of resistance is a continuous clinical challenge.
Transporters that facilitate drug uptake and efflux have been proposed as one potential source of resistance to
tyrosine kinase inhibitor treatment. Our aim was to determine which carriers are responsible for bosutinib transport.
Methods: K562S cells overexpressing the drug transporters ABCB1, ABCG2, and SLC22A1 were generated, characterized
and used in proliferation assay and intracellular uptake and retention assay (IUR). In vivo experiments were
performed in nude mice injected with K562S, K562DOX cells (overexpressing ABCB1), and K562DOX silenced for
ABCB1 (K562DOX/sh P-GP).
Results: The IUR assay using C-14 bosutinib showed that only ABCB1 was responsible for active bosutinib
transport. K562DOX cells showed the lowest intracellular level of bosutinib, while K562DOX cells treated with
the ABCB1 inhibitor verapamil showed intracellular bosutinib levels comparable with parental K562S. Proliferation assays
demonstrated that K562DOX are resistant to bosutinib treatment while verapamil is able to restore the sensitivity to the
drug. Nude mice injected with K562DOX and treated with bosutinib showed very limited response and quickly relapsed
after stopping treatment while K562S as well as K562DOX/sh P-GP remained tumor-free.
Conclusions: Our data suggest that the analysis of ABCB1 expression levels might help determine treatment options for
patients exhibiting resistance to bosutinib.
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Since the discovery of imatinib, the treatment of chronic
myeloid leukemia (CML) is based on tyrosine kinase in-
hibitors (TKIs) that selectively target BCR-ABL, the onco-
protein responsible for the disease. [1] Second-generation
TKIs such as nilotinib and dasatinib have been recently
approved as a first line treatment for CML [2, 3].
Bosutinib is a second-generation dual SRC/ABL TKI,
approximately 10–30 times more potent than imatinib,
and it was recently approved by FDA as a second line
option for CML treatment [4].
Mutations in the kinase domain of BCR-ABL have
been described as the main cause of resistance to all the* Correspondence: sara.redaelli@unimib.it
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creativecommons.org/publicdomain/zero/1.0/TKIs during treatment, but they account for no more
than 50 % of reported cases of resistance [5]. Among
other resistance mechanisms possibly affecting drug effi-
cacy, multidrug-resistance (MDR) transporters that reduce
intracellular drug levels remain a continuing concern. So
far, the following three transporter proteins have been iden-
tified as potential contributors to MDR development
following imatinib treatment: the uptake drug transporter
organic cation transporter 1 (OCT1, encoded by the
SLC22A1 gene) [6], the efflux drug transporter glycoprotein
P (P-GP, MDR1, encoded by the ABCB1 gene) [7], and the
efflux drug transporter breast cancer resistance protein
(BCRP, encoded by the ABCG2 gene) [8]. Changes in the
expression of the drug transporters (downmodulation of
SLC22A1 or overexpression of ABCB1 and ABCG2) or
single-nucleotide polymorphisms in these genes can cause
imatinib resistance [9, 10].rticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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mechanisms. While the efficacy of neither nilotinib nor
dasatinib is affected by changes in SLC22A1 downmodula-
tion [11, 12], nilotinib exhibits a concentration-dependent
interaction with ABCB1 and ABCG2 [13, 14], and dasatinib
is a substrate of both ABCB1 and ABCG2 [15, 16].
Given that bosutinib is a valuable option for the treat-
ment of CML patients [4, 17], we examined whether
SLC22A1, ABCB1, and ABCG2 are involved in its up-
take and efflux with both in vitro assays and an in vivo
model.Fig. 1 Evaluation of drug-transporter expression and functionality. a Evalua
real-time qPCR (RT-qPCR). Housekeeping GAPDH was used for intra-sample
over the expression levels in K562S. Results are the average of three indepe
levels of overexpressing or silenced cells and K562S cells were calculated with tw
limit of statistical significance (** = p < 0.05 *** = p < 0.01). b Evaluation of
whole cell lysate of overexpressing, silenced, and K562S cell lines. Specifi
a loading control. c Intracellular incorporation of known fluorescent subs
123 incorporation for ABCB1 activity analysis, in the middle panel, 4-Di-2-A
ABCG2 analysis. In each graph, the shaded area corresponds to the overe
line to the overexpressing cell lines pre-treated with drug-transporter inhResults
Cell line characterization
To investigate the involvement of ABCB1, ABCG2, and
SLC22A1 in the active transport of bosutinib, we first
characterized expression levels of functionally active
drug transporters ABCB1, SLC22A1, and ABCG2 by
means of RT-qPCR as well as immunoblotting analysis
in the engineered cell lines described in the Materials
and methods section. As expected, RT-qPCR analysis
(Fig. 1a) showed an increased expression of ABCB1,
SLC22A1, and ABCG2 in K562DOX, K562OCT1, andtion of ABCB1, SLC22A1, and ABCG2 drug-transporter expression by
normalization. For each transporter, expression levels were normalized
ndent experiments ± SD. The statistical differences between expression
o-tailed unpaired student’s t-test, and a p value of 0.05 was chosen as the
drug-transporter expression levels by immunoblotting performed on
c antibodies were used for each drug transporter. Actin was used as
trates was evaluated by FACS analysis. On the left panel, rhodamine
SP for SLC22A1 analysis, and in the right panel, pheophorbide A for
xpressing cell line, the solid line to the silenced cell line, the dotted
ibitor, and shortly dashed line to K562S
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ental cells. ABCB1 mRNA levels in K562DOX cells
were approximately 2800-fold higher, SLC22A1 mRNA
levels in K562OCT1 cells approximately 2100-fold, and
ABCG2 mRNA levels in K562BCRP cells approximately
190-fold higher than corresponding mRNA levels ob-
served in K562S parental cells. Stable silencing per-
formed in the same overexpressing cell lines was able
to successfully reduce the transcript levels of the differ-
ent transporters (Fig. 1a). In particular, K562DOX/sh
P-GP cells showed a 87.9 % decrease of ABCB1 levels,
K562OCT1/sh OCT1 cells showed a 99.9 % decrease of
SLC22A1 levels, and K562BCRP/sh BCRP cells showed
a 99.9 % decrease of ABCG2 levels when compared to
the corresponding overexpressing cells. Interestingly,
K562BCRP/sh BCRP cells showed ABCG2 expression
levels even lower than K562S, indicating that endogen-
ous ABCG2 was also silenced.
Immunoblotting analysis confirmed the results ob-
tained by RT-qPCR (Fig. 1b). The three cell lines overex-
pressing drug transporters showed a marked increase in
protein expression compared with both silenced and
K562S cell lines.
We subsequently checked the functionality of the trans-
porters by measuring the intracellular incorporation of
fluorescent substrates specific for each transporter. (Fig. 1c
and Additional file 1: Figure S1). Overexpressing cells
were either pre-treated or untreated with specific drug-
transporter inhibitors. The cells overexpressing either
ABCB1 or ABCG2 showed a decreased intracellular con-
centration of the fluorescent substrates rhodamine 123
(Rho 123) and pheophorbide A (PhA), respectively. As ex-
pected, K562S showed a high level of intracellular fluores-
cent substrates. In silenced cells as well as in cells treated
with the specific drug-transporter inhibitors verapamil(Ver)
or fumitremorgin C (FTC), fluorescence levels were similar
to K562S. Consistent with the role of SLC22A1 in the up-
take of the styrylpyridinium dye ASP, K562OCT1 cells
showed higher ASP incorporation compared to K562S,
while silencing of SLC22A1 or treatment with the specific
SLC22A1 inhibitor amantadine (Ama) [18] led to decreased
ASP incorporation levels similar to K562S. Taken together,
our data confirm that these cell lines overexpress function-
ally active SLC22A1, ABCB1, or ABCG2.
IUR assay for C-14 bosutinib cellular incorporation
The IUR assay has been extensively used to characterize
the interaction of imatinib, nilotinib, and dasatinib with
drug transporters [11, 15, 19, 20]. We used a similar ap-
proach to study the correlation between the expression of
drug transporters and the intracellular concentration
of C-14 bosutinib. While SLC22A1- and ABCG2-
overexpressing cells did not show any marked differ-
ence in C-14 bosutinib incorporation, a statisticallysignificant decrease was observed in K562DOX cells
compared to K562S cells (Fig. 2a, p value 0.0003).
K562DOX/sh P-GP cells exhibited an intermediate
level of bosutinib incorporation, significantly decreased
compared to K562S cell lines (Fig. 2a, p value 0.0006).
These data suggest that ABCB1, but not SLC22A1 or
ABCG2, regulates intracellular levels of bosutinib. We
subsequently evaluated the effect of the specific transporter
inhibitors verapamil, amantadine and fumitremorgin C,
which inhibit ABCB1, SLC22A1, and ABCG2, respectively,
on C-14 bosutinib incorporation (Fig. 2b). While SLC22A1
and ABCG2 overexpressing and silenced cells did not show
significant differences in intracellular C-14 bosutinib levels
when compared with K562S cells, K562DOX cells treated
with verapamil showed a significant increase in intracellular
C-14 bosutinib levels (5.7-fold; p value <0.0001) when com-
pared to the corresponding untreated cells. K562DOX/sh
P-GP exhibited a moderate increase (2.4-fold; p value
0.0008) in bosutinib levels. A modest decrease in bosutinib
levels was observed in K562S cells (1.9 fold; p value 0.007)
relative to cells not treated with verapamil, perhaps due to
verapamil toxicity. Taken together, these data indicate that
ABCB1 (but not SLC22A1 nor ABCG2) is involved in ac-
tive bosutinib transport.
K562DOX resistance to bosutinib and restoration of
sensitivity by verapamil
To assess the functional consequences of ABCB1 involve-
ment in bosutinib efflux, we evaluated the anti-proliferative
activity of bosutinib in K562DOX, K562DOX/sh P-GP, and
K562S cells (Fig. 3a, Additional file 2: Figure S2a and
Table 1). The IC50 value of bosutinib-treated cells is ap-
proximately 6–10 fold higher in K562DOX compared to
either K562S or K562DOX/sh P-GP cells. Similar results
were obtained with imatinib (IC50 fold change 5–8), as ex-
pected, since imatinib is a known ABCB1 substrate.
To test if the inhibition of ABCB1 correlates with a res-
toration of K562DOX sensitivity to imatinib or bosutinib
treatment, we co-treated K562DOX and K562S cells with
verapamil and either bosutinib or imatinib (Fig. 3b). As
expected, the IC50s observed in K562DOX cells de-
creased significantly in presence of verapamil for both
BCR-ABL inhibitors, even at the lowest concentration
tested (p value <0.005). Conversely, the IC50s observed
in K562S cells were not significantly affected by the
presence of verapamil. These results indicate that
ABCB1 overexpression decreases sensitivity to bosuti-
nib, and inhibition of ABCB1 restores sensitivity to
bosutinib in cells overexpressing ABCB1.
The intracellular concentration of bosutinib correlates
with BCR-ABL activity inhibition
Bosutinib, as well as the other TKIs, exerts a pro-apoptotic
activity by directly reducing BCR-ABL kinase activity and
Fig. 2 Intracellular uptake and retention assay. a Intracellular incorporation of C-14 bosutinib is reported as the number of hits obtained from
beta-counter. The results derive from three independent experiments ± SD. For each drug transporter, the statistical difference between overexpressing
or silenced cells and K562S was calculated with two-tailed unpaired student’s t-test, and a p value of 0.05 was chosen as the limit of statistical
significance (** = p < 0.05 *** = p < 0.01 NS, not significant). b C-14 bosutinib intracellular accumulation after drug transporters inhibition. For
each transporter, the cells were pre-treated with specific drug-transporter inhibitors. C-14 bosutinib incorporation obtained with the pre-treatment was
normalized over C-14 bosutinib incorporation in the same cell line without the pre-treatment. Results are an average of three independent experiments.
The statistical difference between untreated and pre-treated samples within each cell line was calculated with two-tailed unpaired student’s t-test, and a
p value of 0.05 was chosen as the limit of statistical significance
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bosutinib treatment on BCR-ABL activity in K562DOX
and K562S cells, we analyzed the phosphorylation levels of
BCR-ABL at different drug concentrations (Fig. 3c and
Additional file 2: Figure S2b). As expected, as bosutinib
concentration increased, BCR-ABL phosphorylation levels
decreased in K562S cells but not in K562DOX cells. How-
ever, when the bosutinib-treated cells were co-treated with
the ABCB1 inhibitor verapamil, a decrease in the phos-
phorylation levels was also observed in K562DOX cells,
while verapamil treatment alone had no effect on BCR-
ABL phosphorylation. These results suggested that inhib-
ition of ABCB1 transporter activity by verapamil caused
intracellular bosutinib accumulation, resulting in the de-
phosphorylation of BCR-ABL.
In vivo effects of ABCB1 overexpression on bosutinib
activity
We next examined bosutinib anti-tumor activity as a
function of ABCB1 overexpression in an in vivoxenograft model. A total of 39 mice were injected with
either K562S (15 animals), K562DOX (14 animals), or
K562DOX/sh P-GP (10 animals) cells. When tumors
reached a weight of 200 mg (approximately day 14 after
injection), mice in each group were randomized in two
subgroups: one received bosutinib at 150 mg/kg, the
other one vehicle alone, 5 days a week for 2 weeks.
Tumor weight was measured for up to 1 month after
treatment termination. As expected, bosutinib treatment
caused tumor regression in mice with K562S. K562DOX
mice exhibited an initial limited response to bosutinib
treatment, but eventually relapsed after treatment was
ended. In contrast, K562DOX/sh P-GP tumors in which
ABCB1 expression was downregulated, showed complete
sensitivity to bosutinib treatment, and regression was
sustained over the period of observation (Fig. 4a–c).
Tumors were recovered from all the mice and ana-
lyzed for ABCB1 and BCR-ABL expression by RT-qPCR.
ABCB1 analysis confirmed that cells derived from
K562DOX tumors maintained high expression levels of
Fig. 3 Effect of ABCB1 overexpression on bosutinib activity. a Proliferation assay on K562DOX, K562DOX/sh P-GP, and K562S. Cells were cultivated
for 72 h in the presence of increasing concentration of either bosutinib or imatinib, and incorporation of tritiated thymidine was evaluated. Results
presented are an average of at least three independent experiments. b Proliferation assay of K562DOX and K562S cells co-treated with verapamil and
either bosutinib or imatinib. Verapamil was used at three selected concentrations, while bosutinib and imatinib were used within the same ranges used
in Fig. 3a. The y axis reports means + SD of bosutinib or imatinib IC50s obtained. Data reported are a mean of three separate experiments. Non-linear
regression was used to evaluate IC50s. c Evaluation of BCR-ABL phosphorylation levels in K562DOX and K562S cell lines, upon bosutinib treatment with
or without verapamil co-treatment. Immunoblotting analysis was performed on whole cell lysates. ABL1 was used as a loading control
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(Additional file 3: Figure S3). Tumor-derived cells were
also used in the proliferation assay to evaluate the sensi-
tivity to bosutinib treatment. IC50s observed in tumor-derived cells were fully comparable with those obtained
using the corresponding cell lines, indicating that in vivo
passage did not affect the behavior of these cells with re-
spect to bosutinib treatment (Fig. 4d). To exclude the
Table 1 IC50 values of bosutinib and imatinib calculated in the
proliferation assay for K562S, K562DOX, and K562DOX/sh P-GP
K562S K562DOX K562DOX/sh P-GP
Bosutinib 6.5 nM 36.1 nM 3 nM
Imatinib 49.3 nM 234.1 nM 28 nM
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bosutinib resistance, RNA was extracted from all the tu-
mors, and the BCR-ABL kinase domain was amplified
and sequenced. In all the cases, no mutations were
found (Additional file 4: Supplementary material). Thus,
the observed resistance to bosutinib treatment most
likely resides in the elevated expression of ABCB1 lead-
ing to a reduced intracellular concentration of bosutinib.
Discussion
The development of second-generation TKIs (dasatinib,
nilotinib, bosutinib) was mainly directed toward over-
coming resistance arising in patients treated with ima-
tinib. Resistance to treatment is largely due to the
presence of point mutations within the BCR-ABL kinase
domain [23], although other mechanisms have been
identified such as: BCR-ABL gene amplification [24] andFig. 4 In vivo evaluation of ABCB1 overexpression effects on bosutinib acti
K562DOX (b), or K562DOX/sh P-GP (c). The treatment length with bosutinib
from K562S, K562DOX, and K562DOX/sh P-GP tumors. Cells were treated w
mean of two independent experiments. p values were calculated, comparin
K562S versus K562S tum (p = 0.38), K562DOX versus K562DOXtum (p = 0.58duplication [25], clonal evolution due to the acquisition
of other chromosomal abnormalities [26], low drug concen-
tration in plasma [27, 28], alternative signaling pathway ac-
tivation [29], epigenetic modifications [30], and MDR due
to drug cellular uptake/efflux impairment [31]. Since many
reports highlight the different transport patterns of nilotinib
and dasatinib compared to imatinib, the two second-
generation inhibitors were suggested as a valid treatment
option to circumvent MDR to imatinib [11, 12]. To date,
MDR affecting bosutinib has been investigated only by
Hegedus and colleagues using in vitro assays [32].
In our work, we analyzed the interaction between
bosutinib and the following three principal drug trans-
porters involved in imatinib transport: ABCB1 [33],
ABCG2 [8], or SLC22A1 [6]. Since the IUR assay has
been extensively used to study multidrug resistance for
imatinib, nilotinib, and dasatinib [11, 15, 34, 35], we used
this assay to examine bosutinib transport. Our results dem-
onstrated that intracellular levels of C-14 bosutinib were
dependent on ABCB1 expression, with decreased intracel-
lular bosutinib levels in cells with high ABCB1, and corres-
pondingly increased intracellular bosutinib levels in cells
with lower ABCB1 levels. In line with these findings, treat-
ment with the ABCB1 inhibitor verapamil increasedvity. a–c Tumor-size measurements in mice injected with K562S (a),
(BOS) is indicated. d Proliferation experiment on ex vivo cells derived
ith increasing concentrations of bosutinib for 72 h. Results are the
g each cell line with the following corresponding tumor-derived cells:
3), and K562DOX/sh P-GP versus K562DOX/sh P-GP tum (p = 0.003)
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either ABCG2 or SLC22A1 had no effect on bosutinib
intracellular accumulation. Similarly, ABCG2 and SLC22A1
inhibition by fumitremorgin C and amantadine, respect-
ively, did not result in any significant difference in intracel-
lular bosutinib levels. These results suggest that in these
cells, ABCG2 and SLC22A1 do not affect bosutinib trans-
port, while ABCB1 catalyzes bosutinib efflux and is there-
fore a potential contributor to bosutinib resistance.
In line with these findings, the decreased intracellular
levels of bosutinib in cells overexpressing ABCB1 are as-
sociated with a higher IC50, whereas treatment with ver-
apamil reversed the effects of ABCB1 overexpression,
but did not significantly affect the response to bosutinib
of cells expressing native levels of ABCB1. As a known
ABCB1 substrate, imatinib behaved similarly to bosuti-
nib. ABCB1 overexpression also inhibited the ability of
bosutinib to reduce BCR-ABL phosphorylation, whereas
verapamil treatment restored bosutinib sensitivity. Thus,
the observed resistance to bosutinib in the ABCB1 over-
expressing cells in vitro is directly related to the in-
creased levels of ABCB1.
ABCB1 overexpression also reduced the anti-tumor
activity of bosutinib in vivo. Experiments on mice
injected with control K562S cells, ABCB1 overexpressing
K562DOX cells as well as K562DOX/sh P-GP, were per-
formed to evaluate the possible effect of drug resistance
on treatment response in vivo. As expected from the lit-
erature [36], K562S clearly responded to treatment, and
the tumors remained not-measurable during the follow-
up period. K562DOX cells initially responded partially to
the treatment, but tumor growth eventually progressed
in all mice. K562DOX/sh P-GP mice responded to the
treatment, and no relapses were observed, confirming
the role of ABCB1 overexpression in the resistance. Ex
vivo analysis performed on tumor cells did not reveal
any difference in BCR-ABL expression between K562S
and K562DOX, excluding the possibility that the relapse
might be due to an increased expression of the onco-
genic protein. Moreover, we also excluded the presence
of mutations as a possible cause of the resistance. Cells
derived from K562DOX tumors showed ABCB1 levels
comparable to the K562DOX cell line, indicating that
they did not lose expression during in vivo experiments.
IC50 values observed in the proliferation assay per-
formed on ex vivo cells are similar with those obtained
in vitro on cell lines not passaged through mice.
To our knowledge, this is the first demonstration of
involvement of ABCB1 in bosutinib transport in both
in vitro and in vivo settings. In previous works, Hegedus
and colleagues [32], by combining several in vitro assays,
concluded that bosutinib is neither a substrate of
ABCB1 nor a substrate of ABCG2. Although our results
agree in excluding a role of ABCG2 in bosutinibtransport, there is a discrepancy with regard to the role
of ABCB1. Such a difference could arise from the differ-
ent assays used by the two groups as well as from the
different concentration ranges tested. However, in vivo
data included in the present work strongly support the
premise that bosutinib is indeed a substrate of ABCB1
and that overexpression of this transporter is able to
confer resistance to this drug.
In summary, we show here that intracellular concen-
trations of bosutinib are affected by the overexpression
of the efflux transporter ABCB1. The reduced intracellu-
lar bosutinib concentration results in a reduction of its
BCR-ABL inhibitory activity, thus leading to resistance.
These data could be useful in the clinical management
of Ph + leukemias. Further studies should be carried out
in BCR-ABL+ patients under treatment with bosutinib to
reveal any correlation between ABCB1 activity and clin-
ical response which might allow the development of
strategies to overcome bosutinib resistance.
Materials and methods
Chemical compounds and reagents
Bosutinib (SKI-606), and C-14 radiolabeled bosutinib
(C-14 bosutinib) were obtained from Pfizer Inc, New
York, NY. Both drugs were dissolved in DMSO to obtain
a 10-mM stock solution. Imatinib (STI-571, Gleevec)
was synthesized by Enrico Rosso, PhD, University of
Venice, Italy and was dissolved in water to obtain a
10-mM stock solution.
Doxorubicin (Sigma-Aldrich, Saint Louis, MO) was
dissolved in DMSO to obtain a final concentration of
10 mM. Geneticin and puromycin, (Euroclone Milan,
Italy) were both dissolved in water to obtain stock solu-
tions of 400 mg/mL and 25 mg/mL, respectively.
Verapamil hydrochloride (Sigma-Aldrich, Saint Louis,
MO) was dissolved in ethanol to obtain a final concen-
tration of 100 mM and used as a selective ABCB1 in-
hibitor. Amantadine hydrochloride (Sigma-Aldrich, Saint
Louis, MO) was dissolved in ethanol to obtain a final
concentration of 1 M and used as a selective SLC22A1
inhibitor. Fumitremorgin C (FTC) (Sigma-Aldrich, Saint
Louis, MO) was dissolved in DMSO to obtain a final
concentration of 1 mM and used as a selective ABCG2
inhibitor.
Rhodamine 123 (Rho-123) (Sigma-Aldrich, Saint
Louis, MO), 4-Di-2-ASP (4-(4-Diethylaminostyryl)-1-
methylpyridinium iodide, ASP) (Invitrogen, Carlsbad, CA),
and Pheophorbide A (PhA) (Frontier Scientific, Logan, UT)
were dissolved in DMSO to obtain a final concentration of
2 mM, 10 mM, and 1 mM, respectively.
Cell lines and cell cultures
K562DOX (kind gift of JP Marie, Université Pierre et Marie
Curie, Paris), K562DOX/sh P-GP (formerly K562DOX-
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University, Austria), K562OCT1, K562OCT1/sh OCT1,
K562BCRP, and K562BCRP/sh BCRP cell lines were de-
rived from the leukemic BCR-ABL+ cell line K562S (K562
imatinib sensitive). Briefly, to obtain K562DOX cell line,
K562S cells were treated with increasing concentrations of
doxorubicin, allowing the selection of K562S cells express-
ing high levels of ABCB1 [37]. K562DOX/sh P-GP cell line
was derived from K562DOX cells with a transposon-based
vector-silencing system, allowing a stable ABCB1 downreg-
ulation [38]. K562OCT1 cell line was obtained by electro-
poration with pcDNA3.1 plasmid carrying a SLC22A1
gene-coding sequence (kind gift of Prof. R. Clark and A.
Giannoudis, Royal Liverpool University hospital, UK)[12].
K562BCRP cell line was obtained by electroporation using
a pcDNA3.1 plasmid carrying a ABCG2 gene-coding se-
quence isolated from the carrier plasmid pCMV6-XL5 ob-
tained from Origene (Rockville, MD). Stable SLC22A1 and
ABCG2 silencing were obtained after stable transfections
with MISSION shRNA plasmid DNA (Sigma-Aldrich, Sant
Louis, MO) in K562OCT1 and K562BCRP cell lines,
respectively. All cell lines were grown in standard con-
ditions with RPMI 1640 medium (Lonza Cambrex,
East Rutherford, NJ) supplemented with 10 % fetal bo-
vine serum (FBS) (Euroclone, Milan, Italy), 2 mM L
glutamine, 100-units/mL penicillin G, 80-μg/mL gentami-
cin, and 20-mM hepes. Cell lines were kept in selective
pressure with the following reagents: 1-μM doxorubicin for
K562DOX, 1-μM doxorubicin, and 1-mg/mL geneticin for
K562DOX/sh P-GP, 1-mg/mL geneticin for K562OCT1
and K562BCRP, 1-mg/mL geneticin, and 1-μM Puromycin
for K562OCT1/sh OCT1 and K562BCRP/sh BCRP.Reverse transcription and qPCR
RNA extraction from all the cell lines was performed
with Trizol reagent (Invitrogen, Carlsbad, CA), accord-
ing to the manufacturer’s protocol. After quantification,
RNA was reverse transcribed to obtain cDNA with
TaqMan kit (Applied Biosystems, Foster City, CA), ac-
cording to the standard protocol. Real-time qPCR (RT-
qPCR) was performed to assess the transcription levels
of ABCB1, SLC22A1, and ABCG2 in all the cell lines.
The following Sybr-Green primers were used for the
analysis: ABCB1 for: 5’- TGGAGGAAGACATGACCA
GG-3’; ABCB1 rev: 5’-CAAGACCTCTTCAGCTACT
GC-3’; SLC22A1 for: 5’-GGGCAGCCTGCCTCGTCA
TG-3’; SLC22A1 rev: 5’-ACCTCCCTCAGCCTGAA
GAC-3’; ABCG2 for: 5’-TTAGGATTGAAGCCAAAG
G-3’; ABCG2 rev: 5’-TAGGCAATTGTGAGGAAAA
TA-3’. The housekeeping gene GAPDH was used for
intra-sample normalization: GAPDH for: 5’-TGCAC
CACCAACTGCTTAGC-3’; GAPDH rev: 5’-GGCATG
GACTGTGGTCATGAG-3’.Immunoblotting
For the evaluation of the expression levels of the drug
transporters, 107 cells were lysed with a specific protocol
for membrane-protein purification. Briefly, K562DOX,
K562DOX/sh P-GP, K562OCT1, K562OCT1/sh OCT1,
and K562S were lysed adding boiling 125-mM Tris–HCl
pH 6.8, SDS 2 % solution supplemented with protease
inhibitors. After resuspension and further boiling, sam-
ples were sonicated and Laemmli buffer was added.
K562BCRP, K562BCRP/sh BCRP, and K562S were lysed
using a hypotonic lysis buffer, 100 mM KCl, 2 mM
MgCl1, 100 mM Tris–HCl (pH 7.4), 1 % SDS supple-
mented with protease inhibitors. After sonication,
Laemmli buffer was added and lysates were heated at
60 °C for 1 h.
Samples were loaded on SDS-PAGE, transferred to
nitrocellulose, and probed with the following different
antibodies: monoclonal ABCB1 antibody C494 (Abcam,
Cambridge UK); polyclonal SLC22A1 antibody AB1
(Sigma-Aldrich, Saint Louis MO) monoclonal ABCG2
antibody BXP-21 (Enzo Life Sciences, AG, Lausen,
Switzerland), and polyclonal actin antibody (Sigma-Aldrich,
Saint Louis MO.
For the evaluation of phosphorylation levels of BCR-ABL,
K562DOX, and K562S, cells were treated with serial dilu-
tions of bosutinib for 8 h at standard conditions. Eventually,
a pre-treatment of 1 h with 5-μM verapamil was performed
to inhibit the ABCB1 activity. Ten million cells were lysed
using a standard protocol described previously [21].
Samples were loaded on SDS-PAGE, transferred to
nitrocellulose, and probed with anti-phosphotyrosine
antibody (clone 4G10, Millipore, Billerica MA). BCR-
ABL levels were probed with anti-c-ABL (K12 clone,
Santa Cruz Biotechnology, Santa Cruz CA).
FACS analysis
Functional activity of ABCB1, SLC22A1, and ABCG2
was evaluated measuring the intracellular accumulation
of known transporter substrates such as: Rho 123 for
ABCB1, ASP for SLC22A1, and Ph A for ABCG2, in
the presence or absence of the selective transporter in-
hibitors. One million cells were incubated for 30 min
with fluorescence substrates and, where indicated, a
2-h pre-treatment with drug-transporter inhibitors was
also performed. Cells were washed twice with ice-cold
PBS before FACS analysis. Rho 123 and ASP incorpor-
ation was determined with the BD FACSort (Becton
Dickinson, San Jose CA); Ph A incorporation was de-
termined with the BD FACScantoI (Becton Dickinson,
San Jose CA).
Intracellular uptake and retention assay (IUR)
Incorporation of C-14 radiolabeled bosutinib (C-14
bosutinib) was evaluated in all the cell lines in the
Redaelli et al. Journal of Hematology & Oncology  (2015) 8:81 Page 9 of 10presence or absence of specific drug-transporter inhibi-
tors. One million cells were resuspended in 2 mL of
complete medium. Drug-transporter inhibitors were added
at selected concentrations (described above) for 2 h. C-14
bosutinib 1 μMwas added for an additional hour of incuba-
tion. Cells were washed thrice with 1-mL ice-cold PBS, re-
suspended in 30-μL PBS, and spotted on a membrane filter.
Radioactivity levels were detected on a 1450 MicroBeta
Trilux β-counter (Perkin Elmer, Waltham MA).Proliferation and co-treatment assay
K562DOX, K562DOX/sh P-GP, and K562S cells were
seeded in a 96-well plate at a concentration of 104
cells/well. Imatinib and bosutinib were added at in-
creasing concentrations. For the co-treatment assay,
imatinib and bosutinib were used at serial concentra-
tions, while the ABCB1 inhibitor verapamil was added
at four different concentrations below its IC50. For
both assays, tritiated thymidine was added after 72 h;
cells were then harvested, and the levels of tritiated
thymidine were evaluated by a 1450 MicroBeta Trilux
β-counter (Perkin Elmer, Waltham MA).In vivo experiments
Six- to eight-week-old female athymic nu/nu mice were
purchased from Harlan Laboratories (San Pietro al
Natisone-Udine, Italy) and kept under standard labora-
tory conditions, according to the guidelines of the Uni-
versity of Milano-Bicocca (Unimib, Monza, Italy). The
study was approved by the Italian Ministry of Public
Health (authorization 176/2009-B). K562S, K562DOX,
and K562DOX/sh P-GP cells were resuspended at a
concentration of 108/ml in a suspension 1:1 PBS-
Matrigel (BD biosciences- Franklin Lakes, NJ USA),
and 0.2 ml were injected sub cutaneously on the right
flank. Tumor weight was calculated by the formula
tumor weight (mg) = (d2 × D/2), where d and D are the
shortest and longest diameters of the tumor, respectively,
measured in millimeters. When tumors average reached
200 mg, treatment started. Mice received 150-mg/kg
bosutinib by oral gavage, and placebo-treated animals
received vehicle alone (0.5 % methylcellulose-0.4 %
Tween 80). Mice were treated once a day for 5 days/
week for 2 weeks [21]. After sacrifice, tumors were col-
lected, and recovered cells were used to perform fur-
ther analysis.Statistical analysis
All the statistical analysis, data, and graph elaborations
were run on GraphPad software analysis program
(Prism, San Diego, CA).Additional files
Additional file 1: Supplementary Figure S1. Confocal microscopy
analysis of ABCB1 activity. K562S and K562DOX cells were treated as
previously described for FACS analysis (Fig. 1), and an equal amount of
cells were acquired using a Zeiss LSM 710 confocal laser-scanning microscope
(Jena, Germany). Samples were acquired both in contrast phase and using
specific settings for rhodamine excitation and emission (Laser 561 nm and an
emission window between 570 and 640 nm) using a ×20 air-phase or
×40 oil-phase objective applying also an additional hardware zoom to
better define the fluorescent subcellular localization. The acquisition
parameters were set on the signal deriving from the K562S samples
and kept constant for all the other samples. Phase contrast images were
acquired in order to assess the presence of a comparable morphology and
cell number in all the analyzed samples.
Additional file 2: Supplementary Figure S2. A) IC50 values of imatinib
and bosutinib. IC50 values (mean ± SD) of imatinib and bosutinib calculated
from non-linear regression-proliferation curves reported in Fig. 3a. The
statistical differences were calculated with two-tailed unpaired student’s t-test,
and a p value of 0.05 was chosen as the limit of statistical significance. B)
Densitometric analysis. Western blot (Fig. 3c) was analyzed by densitometry
normalizing the anti-phosphotyrosine signal over its loading control (anti-abl).
Relative signal intensity in the control lane was set as 100 %.
Additional file 3: Supplementary Figure S3. Evaluation of ABCB1
expression by real-time qPCR in cells recovered from tumor and the
corresponding cell line. Housekeeping GAPDH was used for intra-sample
normalization. Expression levels were normalized over the levels in
K562S. Results are the average of three independent experiments ± SD.
The statistical data were calculated with two-tailed unpaired student’s t-test,
and a p value of 0.05 was chosen as the limit of statistical significance.
Additional file 4: Supplementary material. Sanger sequencing
analysis of the Abl kinase domain in tumor derived cells.Competing interests
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